Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING)

Cancer Treatment and Research Communications · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles